The first batch of nanoparticles for the anti-nicotine vaccine was synthesized in Khimki

Selecta (RUS) has successfully implemented technology transfer

Rusnano Press Center

Selecta (RUS), the Russian division of the Rusnano portfolio company Selecta Biosciences, Inc., synthesized the first batch of TSV™ nanoparticles with an active component of the anti-nicotine vaccine. Selecta (RUS) employees successfully reproduced the technology of creating nanoparticles at the company's research center in Khimki after training at the Boston division of Selecta Biosciences, Inc. The correspondence of the sizes of the synthesized particles to the specified parameters, which is critical for the nanovaccine, was confirmed using the dynamic light scattering method. The next step is a long—term stability analysis of nanoparticles, as well as immunological experiments on animals, which should confirm the biological activity of the drug.

Portal "Eternal youth" http://vechnayamolodost.ru14.03.2013